Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Depression is a pervasive mental health condition affecting millions of people worldwide. It can manifest in various ways, from persistent sadness to a lack of energy or interest in daily activities.

A new treatment being offered by High Plains Mental Health Center is proving to be life-changing for some people suffering ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

A trial for psilocybin therapy to treat depression is being opened to Vancouver Island applicants. Psilocybin is a ...

Although antidepressants are still commonly used to treat depression, one-third of individuals are unresponsive to medication, resulting in what is known as treatment-resistant depression (TRD). Hence ...

"Mushrooms or magic mushrooms are not narcotic substances and cannot be treated as psychotropic substances under the Narcotic ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...